Lyell Cost Of Revenue vs Net Income Analysis
| LYEL Stock | USD 0.92 0.01 1.10% |
Lyell Immunopharma financial indicator trend analysis is infinitely more than just investigating Lyell Immunopharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lyell Immunopharma is a good investment. Please check the relationship between Lyell Immunopharma Cost Of Revenue and its Net Income accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.
Cost Of Revenue vs Net Income
Cost Of Revenue vs Net Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lyell Immunopharma Cost Of Revenue account and Net Income. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Lyell Immunopharma's Cost Of Revenue and Net Income is -0.41. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Net Income in the same time period over historical financial statements of Lyell Immunopharma, assuming nothing else is changed. The correlation between historical values of Lyell Immunopharma's Cost Of Revenue and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Lyell Immunopharma are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Cost Of Revenue i.e., Lyell Immunopharma's Cost Of Revenue and Net Income go up and down completely randomly.
Correlation Coefficient | -0.41 |
| Relationship Direction | Negative |
| Relationship Strength | Very Weak |
Cost Of Revenue
Cost of Revenue is found on Lyell Immunopharma income statement and represents the costs associated with goods and services Lyell Immunopharma provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Lyell Immunopharma financial statement analysis. It represents the amount of money remaining after all of Lyell Immunopharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most indicators from Lyell Immunopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lyell Immunopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.At this time, Lyell Immunopharma's Selling General Administrative is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 541.02 this year, although the value of Issuance Of Capital Stock will most likely fall to 0.00.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 1.2M | 7.1M | 23.5M | 24.6M | Net Interest Income | 1.2M | 7.1M | 23.5M | 24.6M |
Lyell Immunopharma fundamental ratios Correlations
Click cells to compare fundamentals
Lyell Immunopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.79) | Quarterly Revenue Growth 0.36 | Return On Assets (0.19) | Return On Equity (0.33) |
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.